Biogen Idec, Inc. (Massachusetts) Suddenly Struggling To Keep Up With The Biotech Joneses

Up from $42.92 in March of 2009, Biogen Idec Pharmaceuticals has posted an “eight-bagger” in terms of returns for their loyal longs. Does the company's expected growth going forward justify further gains? Biogen Idec (NASDAQ: BIIB) shareholders have been rewarded handsomely for holding the stock for the long term over the years. After the March peak at $358.89, however, the stock has failed to approach new all-time highs.

Hey, check out all the research scientist jobs. Post your resume today!